BeOne Medicines (ONC) Stock Price, News & Analysis

Company Overview

BeOne Medicines is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation cancer immunotherapies. The company’s core focus lies in engineering T-cell engager antibodies designed to recruit and activate a patient’s own immune system against solid tumors. By leveraging a proprietary platform for bispecific antibody design, BeOne Medicines aims to create therapies with enhanced specificity and safety profiles compared with conventional approaches.

The company’s pipeline comprises multiple early-stage programs directed at validated tumor-associated antigens. These candidates are advancing through preclinical studies, with plans to initiate first-in-human trials in the near term. BeOne Medicines applies a rational target selection process and modular antibody format to optimize pharmacokinetics and tumor penetration, seeking to address unmet needs in indications that have shown limited response to existing treatments.

Guided by a multidisciplinary management team with extensive experience in oncology drug development, BeOne Medicines collaborates with leading academic institutions and contract research organizations to accelerate its programs. The company maintains strategic partnerships to support process development, manufacturing, and regulatory strategy, positioning it to progress its immuno-oncology candidates toward clinical milestones and potential commercialization.

Key Stats

• Today's Range: $326.69 to $332.17
• 50-Day Range: $279.16 to $351.13
• 52-Week Range: $170.99 to $351.27
• Volume: 169,973 shs
• Average Volume: 337,796 shs
• Market Capitalization: $36.09 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $336.30
• Consensus Rating: Buy

BeOne Medicines Stock Analysis - MarketRank™

BeOne Medicines scored higher than 37% of companies evaluated by MarketBeat, and ranked 726th out of 946 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.7 / 5
• Analyst Rating: Buy

Consensus Rating

BeOne Medicines has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for BeOne Medicines is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

BeOne Medicines has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BeOne Medicines are expected to grow in the coming year, from ($5.82) to $0.71 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BeOne Medicines is -190.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BeOne Medicines is -190.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BeOne Medicines has a P/B Ratio of 9.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.37% of the float of BeOne Medicines has been sold short.

Short Interest Ratio / Days to Cover

BeOne Medicines has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BeOne Medicines does not currently pay a dividend.

Dividend Growth

BeOne Medicines does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.37% of the float of BeOne Medicines has been sold short.

Short Interest Ratio / Days to Cover

BeOne Medicines has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.67

News Sentiment

BeOne Medicines has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for BeOne Medicines this week, compared to 7 articles on an average week.

Search Interest

13 people have searched for ONC on MarketBeat in the last 30 days. This is an increase of 333% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added BeOne Medicines to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, BeOne Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $55,372,357.00 in company stock.

Percentage Held by Insiders

Only 6.62% of the stock of BeOne Medicines is held by insiders.

Percentage Held by Institutions

48.55% of the stock of BeOne Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ONC Stock Analysis - Frequently Asked Questions

How have ONC shares performed this year?

BeOne Medicines' stock was trading at $223.50 at the beginning of 2025. Since then, ONC shares have increased by 47.2% and is now trading at $329.07.

How were BeOne Medicines' earnings last quarter?

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) announced its earnings results on Wednesday, August, 6th. The company reported $0.84 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.36. The firm earned $1.32 billion during the quarter, compared to analyst estimates of $1.24 billion. BeOne Medicines had a negative trailing twelve-month return on equity of 1.22% and a negative net margin of 3.89%.

Who are BeOne Medicines' major shareholders?

Top institutional shareholders of BeOne Medicines include Primecap Management Co. CA (4.64%), Temasek Holdings Private Ltd (0.92%), Marshall Wace LLP (0.43%) and Baird Financial Group Inc. (0.31%). Insiders that own company stock include Bros Advisors Lp Baker, Aaron Rosenberg, Xiaodong Wang, Xiaobin Wu, Titus B Ball, Lai Wang, Lai Wang, John Oyler, Corazon (Corsee) D Sanders, Corazon (Corsee) D Sanders and Chan Henry Lee.
View institutional ownership trends.

How do I buy shares of BeOne Medicines?

Shares of ONC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/06/2025
• Today: 9/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ONC
• Previous Symbol: NASDAQ:ONC
• CIK: 1651308
• Web: N/A
• Phone: 13459494123
• Fax: N/A
• Employees: 11,000
• Year Founded: N/A

Price Target and Rating

• Average Price Target for BeOne Medicines: $336.30
• High Price Target: $385.00
• Low Price Target: $259.00
• Potential Upside/Downside: +2.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.11
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.73)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$644.79 million
• Net Margins: -3.89%
• Pretax Margin: -1.39%
• Return on Equity: -1.22%
• Return on Assets: -0.72%

Debt

• Debt-to-Equity Ratio: 0.04
• Current Ratio: 1.95
• Quick Ratio: 1.72

Sales & Book Value

• Annual Sales: $3.81 billion
• Price / Sales: 9.49
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $34.10 per share
• Price / Book: 9.67

Miscellaneous

• Outstanding Shares: 109,660,000
• Free Float: 102,403,000
• Market Cap: $36.15 billion
• Optionable: N/A
• Beta: 0.21